BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Sirona Biochem To Present Kel-01 At Cosmetic 360 In Paris, France

  Sirona Biochem Corp. announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on October 18-19, 2017.

  October 16, 2017

   · 

  2 min read
• FDA

  Anika Announces Regulatory Approval For MONOVISC In Australia For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints

  Anika Therapeutics today announced that regulatory authorities in Australia granted approval to MONOVISC.

  October 16, 2017

   · 

  5 min read
• Business

  Vertex To Announce Third Quarter 2017 Financial Results On October 25

  Vertex will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

  October 16, 2017

   · 

  1 min read
• Drug Development

  PROMETRIKA To Coordinate Second Phase I Trial For MD Anderson’s Institute For Applied Cancer Science

  PROMETRIKA, LLC, a boutique full service Clinical Research Organization (CRO), is coordinating a Phase 1 trial for The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science.

  October 16, 2017

   · 

  1 min read
• Policy

  FDA Accepts Bristol-Myers Squibb’s Application For Opdivo (Nivolumab) In Patients With Resected High-Risk Advanced Melanoma And Grants Priority Review

  Bristol-Myers Squibb Company announced today that FDA has accepted for priority review its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

  October 16, 2017

   · 

  32 min read
• Business

  Senseonics Holdings, Inc. Schedules Third Quarter 2017 Earnings Release And Conference Call For October 31, 2017 At 4:30 P.M. Eastern Time

  Senseonics Holdings, Inc. today announced that it plans to release its third quarter 2017 financial results after market close on Tuesday, October 31, 2017.

  October 16, 2017

   · 

  1 min read
• Policy

  Mylan Invalidates Allergan’s Patents on Restasis

  Mylan today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents relating to Restasis invalid based on obviousness.

  October 16, 2017

   · 

  5 min read
• Business

  Dentsply Sirona Announces Additions to Executive Leadership Team

  Dentsply Sirona announced the appointment of two new Executive Leadership Team members, effective immediately.

  October 16, 2017

   · 

  5 min read
• Drug Development

  Inovio Pharmaceuticals Begins Phase Ib/II Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer

  Inovio announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab in combination with Inovio’s INO-5401 and INO-9012.

  October 16, 2017

   · 

  7 min read
• Novo Nordisk - Share Repurchase Programme

  Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR).

  October 16, 2017

   · 

  1 min read